For patients whose time to progression on immediate prior therapy was >18 months, median progression-free survival (“PFS”) was 12.4 months with gedatolisib + palbociclib + fulvestrant (“gedatolisib...
These three up-and-coming stocks are delivering massive 2025 gains and may have more room to run as key catalysts unfold
MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract...
MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation...
MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion...
Presented detailed efficacy and safety results from the PIK3CA wild-type (“WT”) cohort of the Phase 3 VIKTORIA-1 clinical trial at a late breaking oral presentation at the 2025 European Society for...
MINNEAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will...
MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation...
The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +1.07%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.12%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.30%. December E-mini...
The S&P 500 Index ($SPX ) (SPY ) today is up +1.01%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.86%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.29%. December E-mini S&P futures (ESZ25...